Biotech Autist (@BiotechAutist) header
Biotech Autist (@BiotechAutist) profile picture

Biotech Autist

@BiotechAutist

Regulatory Arbitrage. I short certainty.

Joined August 2017
  • Tweets905
  • Following185
  • Followers2.6K
60Media
Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)Photo by Biotech Autist (@BiotechAutist)
$REPL Quiet now.
Image from Biotech Autist (@BiotechAutist)
Biotech Autist (@BiotechAutist) profile pictureBiotech Autist
@BiotechAutistApr 6
1/ I'm all in short on $REPL They got rejected because the filed study was not adequate and well-controlled. Their answer was not to produce a new study. Their answer was to run the same one back. CRL is coming馃У
14
87
30,566
$MNOV
Image from Biotech Autist (@BiotechAutist)
Biotech Autist (@BiotechAutist) profile pictureBiotech Autist
@BiotechAutistSep 24
I'm SHORT $MNOV. They changed the test mid-trial to make life easier. They can't change the drug. It fails馃У
4
17
1,740
I'm SHORT $MNOV. They changed the test mid-trial to make life easier. They can't change the drug. It fails馃У
4
3
17
5,938
more replies
19/ They've done this before. March 2007, same CEO. Headline: "MediciNova Announces Positive Clinical Results." Third paragraph: the drug missed the main goal the trial was designed to hit. Their 2007 deck promised the next big MS trial "as early as 08Q2." Kids born that quarter can vote now. Still no big MS trial.
Image from Biotech Autist (@BiotechAutist)
1
5
588
20/ Scoreboard: $443.6 million lost since they started. Approved drugs: zero. This trial misses. Short it. And if the headline says "positive" anyway, short more. Yuichi Iwaki has done it before. $MNOV goes to $1-1.5.
2
4
524
Load more